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The effect of the heart rate 
lowering drug Ivabradine on 
hemodynamics in atherosclerotic 
mice
R. Xing  1, A. M. Moerman1, R. Y. Ridwan2,3, K. van Gaalen1, E. J. Meester1,3,  
A. F. W. van der Steen1, P. C. Evans4, F. J. H. Gijsen1 & K. Van der Heiden1
The heart rate lowering drug Ivabradine was shown to improve cardiac outcome in patients with 
previous heart failure. However, in patients without heart failure, no beneficial effect of Ivabradine was 
observed. Animal studies suggested a preventive effect of Ivabradine on atherosclerosis which was 
due to an increase in wall shear stress (WSS), the blood flow-induced frictional force exerted on the 
endothelium, triggering anti-inflammatory responses. However, data on the effect of Ivabradine on 
WSS is sparse. We aim to study the effect of Ivabradine on (i) the 3D WSS distribution over a growing 
plaque and (ii) plaque composition. We induced atherosclerosis in ApoE−/− mice by placing a tapered 
cast around the right common carotid artery (RCCA). Five weeks after cast placement, Ivabradine 
was administered via drinking water (15 mg/kg/day) for 2 weeks, after which the RCCA was excised 
for histology analyses. Before and after Ivabradine treatment, animals were imaged with Doppler 
Ultrasound to measure blood velocity. Vessel geometry was obtained using contrast-enhanced 
micro-CT. Time-averaged WSS during systole, diastole and peak WSS was subsequently computed. 
Ivabradine significantly decreased heart rate (459 ± 28 bpm vs. 567 ± 32 bpm, p < 0.001). Normalized 
peak flow significantly increased in the Ivabradine group (124.2% ± 40.5% vs. 87.3% ± 25.4%, p < 0.05), 
reflected by an increased normalized WSS level during systole (110.7% ± 18.4% vs. 75.4% ± 24.6%, 
p < 0.05). However, plaque size or composition including plaque area, relative necrotic core area 
and macrophage content were not altered in mice treated with Ivabradine compared to controls. We 
conclude that increased WSS in response to Ivabradine treatment did not affect plaque progression in a 
murine model.
Atherosclerosis is characterized by the accumulation of lipids, fibrous tissues and inflammatory cells in the arte-
rial wall. The initiation of atherosclerosis is regulated by low wall shear stress (WSS), while high WSS is known to 
be athero-protective in the early phase of the disease1,2. When the disease progresses, the plaques can grow to the 
extent that they affect lumen diameter, resulting in changes in WSS over the plaque3–5. How these changes in WSS 
affect progression of the disease is still a topic under investigation3,4.
Increased heart rate has been established as a risk factor for cardiovascular disease in a healthy population and 
in a population with a history of various heart diseases6–8. The heart rate lowering drug Ivabradine acts on the 
cardiac pacemaker If ion current which is highly expressed in the sinoatrial node. By inhibiting the If current, the 
diastolic depolarization phase is delayed, thus the heart rate is selectively reduced9. Several clinical studies showed 
that Ivabradine improved cardiac outcome in patients who had coronary artery disease with previous heart fail-
ure8,10,11. However, a recent study suggested no beneficial effect of Ivabradine on patients who had coronary artery 
disease without heart failure12. Since the reported results are event-based only, size and composition of these 
coronary artery plaques is unknown, and hence the effect of Ivabradine on plaque progression is not conclusive.
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Experimental evidence of lowering heart rate on reduced plaque burden was previously demonstrated by 
Beere et al.13,14. Animal studies have shown that Ivabradine reduced heart rate and decreased oxidative stress, 
prevented endothelial dysfunction and thus reduced atherosclerosis15–20. These studies suggested that the effect of 
Ivabradine was exerted via alteration of the hemodynamic environment. However, the mechanism of the benefi-
cial effect of Ivabradine on hemodynamics has not been established. We and others suggested that by increasing 
the duration of the diastolic phase and thus lowering the heart rate, Ivabradine indirectly alters the local hemo-
dynamic environment16,21. In our previous study, using LDLR−/− mice, an increased WSS in the aortic arch was 
observed upon treatment with Ivabradine21. WSS was calculated using averaged flow measurement from multiple 
mice and using the geometry of one mouse. Also, the effect of Ivabradine on plaque progression and/or compo-
sition was not investigated. Most animal studies focused on the preventive effect of Ivabradine: the animals were 
treated with Ivabradine simultaneously with the onset of high fat diet. This does not reflect the clinical situation 
where patients with known cardiovascular disease showed improved secondary outcomes after Ivabradine treat-
ment8,10,11. In other studies, endothelial dysfunction was first induced by 4–6 weeks of high fat diet and then 
Ivabradine was administered17,21. However, this duration of high fat diet was too short to induce formation of an 
advanced plaque. Therefore, a curative study design where Ivabradine treatment is administered after the forma-
tion of an advanced plaque is more clinically relevant.
Therefore, in this study, we performed a detailed analysis of the effect of Ivabradine on WSS and atheroscle-
rotic plaque progression and composition in a mouse model of atherosclerosis. We used the well-established 
cast mouse model on ApoE−/− mice, in which a plaque with characteristics of a vulnerable phenotype is induced 
upstream of the cast. After formation of this plaque, animals were treated with Ivabradine and its effect on blood 
flow parameters, WSS, and its potential effect on plaque composition was analyzed.
Methods
To study wall shear stress (WSS) in vivo, we need to acquire parameters including mouse-specific vessel geometry, 
blood flow velocity and vessel diameter. The vessel geometry can be obtained using high-resolution micro-CT 
imaging, while blood flow velocity and vessel diameter can be assessed using ultrasound imaging. This informa-
tion can then be processed and used to compute WSS.
Animals, cast placement and Ivabradine treatment. Female ApoE−/− mice on a C57BL/6 J genetic 
background (n = 18) were purchased from Charles River (Maastricht, The Netherlands). At 13 weeks of age, nor-
mal chow diet was replaced with an atherogenic high fat diet (Altromin Spezialfutter, Germany) and provided ad 
libitum. Cast surgery was performed two weeks later on the animals under isoflurane-induced anesthesia5,22,23. A 
constrictive cast with an internal diameter of 400 μm tapering to 200 μm over 1.5 mm was placed around the right 
common carotid artery (RCCA), leading to changes in local WSS environment and subsequent plaque develop-
ment. Five weeks after the cast placement, mice (n = 9) were treated with Ivabradine in drinking water ad libitum 
for a duration of 2 weeks (162 mg/L, equivalent to 15 mg/kg/day) or with regular drinking water as control (n = 9). 
This optimal dose was determined in our previous publication21, where we demonstrated a biological effect of 
Ivabradine on the arterial wall and a reduction in heart rate by approximately 20%, proportional to that observed 
in Ivabradine-treated patients10.
The amount of drinking water was monitored for mice and refreshed twice a week. A pre-study power analysis 
was performed based on our previous experience with this dose of Ivabradine21, where the smallest significant 
biological effect of Ivabradine on the arterial wall was observed in the endothelial VCAM-1 expression in the 
outer curvature of the mouse aorta (reduction by 80% with a standard deviation of 45%). To reach a power of 
80%, 5 experimental animals are required to obtain statistical significance (p < 0.05). An estimated 40% loss of 
experimental animals due to the multiple anesthesia moments was incorporated and ethical approval for 9 exper-
imental animals per group was obtained. All animal experiments were performed conform to the guidelines from 
Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes, and 
were approved by the ethical committee of Erasmus MC Rotterdam.
Animal Imaging Experiments. Doppler Ultrasound Imaging was performed using Vevo 2100 
(VisualSonics). Blood velocity waveform upstream of the RCCA was measured with a 40-MHz transducer in 
the pulse-wave mode. The distinction between the systole and diastole of the cardiac cycle was determined by 
the dicrotic notch identified on the RCCA blood velocity waveforms24. RCCA diameter at systole or diastole was 
measured in the M-mode at the same location of the velocity measurement, allowing conversion of blood velocity 
(mm/s) to flow (mm3/s) assuming a parabolic velocity profile and a circular geometry of the vessel cross-section. 
The parameters were determined at 5 weeks after cast placement (t = 0, baseline) and 3 days after the treatment 
of Ivabradine (t = 3) in both control and Ivabradine-treated mice. Animals were anesthetized under isoflurane 
(1.5–3% with 1 L/min oxygen) during the measurement while heart rate was measured by ECG during 24–38 min 
after beginning anesthesia. The body temperature was maintained between 35.8 °C to 37.7 °C during the proce-
dure by a heating pad and a heating lamp.
At t = 3, contrast-enhanced micro-CT imaging was performed using a Quantum FX (PerkinElmer). The scan-
ning parameters used were 90kvp, 160 µA with 20 mm field of view and a scan duration of 4.5 min. Contrast 
agent eXIA 160 (Binitio Biomedical, Canada) was used with an injection dose of 150 µl/25 grams of body weight. 
Micro-CT imaging was performed directly before the ultrasound imaging. Images in Hounsfield unit (HU) were 
reconstructed with an isotropic resolution of 40 µm. However, 7 out of 18 mice died 1–2 days after the imaging 
point at t = 3. This premature death is probably due to the combination of repeated anesthesia and the use of 
imaging contrast agent. As a result, WSS simulation (n = 5 control and n = 5 Ivabradine-treated mice) and histol-
ogy (n = 4 control and n = 5 Ivabradine-treated mice) analyses were performed in a subset of animals.
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RCCA lumen surface reconstruction and CFD simulation. RCCA lumen geometry was segmented 
using previously established protocols in MeVisLab (MeVisLab 2.2.1) and Matlab (Matlab R2017a)25. RCCA 
lumen surface was reconstructed from its origin at the bifurcation of the brachiocephalic artery, to its bifurcation 
into the internal and external carotid artery.
RCCA lumen surface was smoothed using the Vascular Modelling Tool Kit (VMTK 1.2). The superfluous ends 
at the proximal and distal side of the vessel surface were clipped and flow extensions were added. A volume mesh 
with prism layers was then generated using ICEM (ICEM-CFD 14.5, Ansys) and a mesh-independent solution 
with approximately 580,000 elements was obtained. The Surface area of the RCCA inlet was derived, enabling the 
calculation of location-specific blood flow velocity as an inlet boundary condition.
The Navier-Stokes equations were solved by computational fluid dynamics (CFD) using Fluent (Fluent 17.1, 
Ansys). Blood was modeled to be incompressible. A constant viscosity of 3.5 × 10−3 kg·m−1·s−1 was used, and 
vessel wall was assumed to be rigid. A parabolic velocity profile was imposed as inlet boundary condition. The 
time-dependent blood flow wave form was derived from Doppler velocity measurements. For the outlet bound-
ary condition, zero pressure was used. Time-dependent flow simulations were performed for 2 cardiac cycles with 
100 time steps per cycle. WSS was derived from the computed velocity field. Finally, post-processing and analysis 
were performed in CFD-Post (CFD-Post 14.5, Ansys) and Matlab to quantify time-averaged WSS (TAWSS), 
TAWSS during systole and diastole, and peak WSS.
Histological and immunohistochemical analyses. RCCA vessel samples of Ivabradine-treated mice 
(n = 5) and control mice (n = 4) were harvested and embedded in paraffin for histological analysis. Serial sections 
of 5 µm thick were collected every 50 µm, from the brachiocephalic bifurcation proximally to the carotid bifurca-
tion distally. The sections were stained with H&E for general plaque morphology, Resorcin-Fuchsin for collagen, 
CD31 for endothelium (1:20, Dianova, Germany) and CD68 for macrophages (1:100, Bio-Rad, USA). Plaque area 
and macrophage area were quantified (BioPix iQ3.2). Necrotic core was defined as a-cellular, a-nuclear areas, free 
of H&E staining, essentially as described previously5
Statistical analysis. Data analysis was performed in Matlab (Matlab R2017a) and RStudio (RStudio 1.0.153). 
Data are presented as mean ± SD. The normality of the data was evaluated by Shapiro–Wilk test. If the data was 
normally distributed, the student t-test was used for further analyses. For data that was not normally distributed, 
a non-parametric Wilcoxon signed-rank test was used. Differences between the Ivabradine-treated group and 
the control group were evaluated using an unpaired, two-tailed students’ t-test or Wilcoxon signed-rank test. 
Differences between the 2 time points (t = 0 vs. t = 3) within the same group were evaluated using a paired, 
two-tailed students’ t-test or non-parametric Wilcoxon signed-rank test. The results were considered significant 
if the p-value < 0.05.
Results
Ivabradine reduced heart rate. Heart rate at baseline (t = 0 days) and after administration of Ivabradine 
(t = 3 days) are shown in Fig. 1A. At baseline, there was no difference in heart rate between the control and the 
treatment group (495 ± 64 bpm vs. 491 ± 83 bpm, p > 0.05). After 3 days treatment, heart rate in mice treated 
with Ivabradine was 459 ± 28 bpm, which was significantly lower compared to that of the control group (567 ± 32 
bpm, p < 0.001). Interestingly, heart rate in control mice increased significantly from baseline to 3 days treatment 
(p < 0.05). The normalized values are listed in Table 1. Compared to the control mice, heart rate of the Ivabradine-
treated mice reduced 18.1%. The data for each individual mouse are presented in the Supplemental Fig. 1.
Ivabradine prolonged the duration of the diastolic phase. The reduction of heart rate after the 
administration of Ivabradine resulted in a prolonged cardiac cycle compare to control mice (p < 0.001, data not 
shown). The effect of Ivabradine was further investigated by dividing the cardiac cycle into the systolic and the 
diastolic phase. As shown in Fig. 1B, Ivabradine did not alter the duration of the systolic phase (0.028 ± 0.010 s vs. 
0.029 ± 0.004 s). However, the diastolic phase was significantly longer in mice treated with Ivabradine compared 
to that of the control group (Fig. 1C, 0.072 ± 0.008 s vs. 0.096 ± 0.015 s, p < 0.01). Table 1 shows the normalized 
cardiac duration of the systolic and the diastolic phase. The data for each individual mouse are presented in the 
Supplemental Fig. 2.
Figure 1. Differences of cardiac parameters between control mice (n = 9) and Ivabradine-treated mice (n = 9). 
The graphs are shown as mean ± standard deviation. (A) Heart rate; (B) Duration of the systolic phase; (C) 
Duration of the diastolic phase. Note: *p < 0.05, **p < 0.01, ***p < 0.001.
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Ivabradine did not alter blood flow in the RCCA. The effect of Ivabradine on the flow environment 
in the RCCA was studied. There were no differences in absolute time-averaged or peak blood flow between the 
Ivabradine-treated mice and the control mice. However, normalized peak flow was 124.2% ± 40.5% after the 
Ivabradine treatment, while it decreased to 87.3% ± 25.4% in the control group (p < 0.05). The data for each indi-
vidual mouse are presented in the Supplemental Fig 3.
Ivabradine affected wall shear stress in the RCCA during systole. Different WSS parameters in the 
healthy segment and the plaque segment of the RCCA were investigated. After normalization, TAWSS during 
systole in the RCCA was significantly higher in animals treated with Ivabradine compared to the control mice 
(Table 2, p < 0.05). Figure 2 illustrates the distribution of TAWSS during systole in the RCCA of a representative 
mouse. Treatment of Ivabradine significantly increased TAWSS during systole in both the healthy segment and 
the plaque segment (Fig. 2C). Also, peak WSS increased significantly in the upstream RCCA after the treatment 
of Ivabradine (p < 0.05, Table 2). However, there were no significant differences between the control and the 
Ivabradine-treated mice in terms of the other WSS parameters investigated, including TAWSS or TAWSS during 
diastole. Table 2 summarizes the normalized WSS parameters. The data for each individual mouse are presented 
in the Supplemental Figs 4 and 5.
Ivabradine did not change plaque composition. After 2 weeks of Ivabradine treatment, RCCA vessel 
samples were harvested for histological analyses. Plaque compositional parameters including plaque area, plaque 
length, relative necrotic core area and relative macrophage area were characterized. None of the parameters were 
significantly different between the control group and the Ivabradine-treated group (Table 3).
Discussion
Our study evaluated the effect of Ivabradine on heart rate and its subsequent effect on blood flow, WSS and plaque 
composition using a mouse model in which an advanced plaque was present. We demonstrated that Ivabradine 
significantly prolonged the duration of the diastolic phase, thus extending the entire cardiac cycle and reducing 
heart rate. Time averaged blood flow over the complete heart cycle did not change. Normalized peak blood flow 
was significantly higher in mice treated with Ivabradine, leading to a significant increase in normalized TAWSS 
during systole. These changes in WSS did not alter the plaque composition after 2 weeks of Ivabradine treatment.
Heart rate in mice treated with Ivabradine was 18.1% lower than the control mice, comparable to the values 
observed in other studies15–20,26. The control group showed an increase in heart rate. Such an increase was also 
reported by Drouin et al. in dyslipidaemic mice during aging15. This could be due to a combined effect of anes-
thesia and/or the use of contrast agent. To correct for this, we normalized the data to the baseline measurements. 
Ivabradine increased normalized peak blood flow in the RCCA to 124.2% ± 40.5% in our mice, which is compara-
ble to the increase we measured in a single murine aorta previously21. In pigs of myocardial ischemia/reperfusion 
model, Heusch et al. reported a 67.5% increase in myocardial blood flow after the administration of Ivabradine27. 
In patients diagnosed with stable coronary artery disease, Ivabradine also induced an increase in flow i.e. a 12.4% 
increase in time-averaged peak coronary flow velocity during hyperemia. In our study, the increase in systolic 
blood flow did result in an increase in TAWSS during systole to 110.7% ± 18.2%, comparable to the increase in 
TAWSS we found previously in the murine aorta21. However, the TAWSS over the entire cardiac cycle was not 
affected by Ivabradine. Based on our current findings and the existing literature, Ivabradine treatment, regardless 
Parameter Control (n = 9)
Ivabradine 
(n = 9) P-value
Heart Rate 116.8% ± 22.1% 95.9% ± 17.2% 0.03*
Systolic Duration 89.5% ± 14.4% 106.4% ± 29.1% 0.14
Diastolic Duration 90.2% ± 22.5% 108.2% ± 31.0% 0.18
Average Blood Flow 90.3% ± 35.9% 125.8% ± 48.5% 0.10
Peak Blood Flow 87.3% ± 25.4% 124.2% ± 40.5% 0.03*
Table 1. Normalized Cardiac and Flow Parameters.
WSS Parameter Control (n = 5) Ivabradine (n = 5) P-value
TAWSS Healthy Segment 77.9% ± 21.2% 99.7% ± 22.9% 0.16
TAWSS Plaque Segment 77.4% ± 21.4% 99.4% ± 23.4% 0.16
TAWSS Systole Healthy Segment 74.6% ± 21.5% 110.7% ± 18.2% 0.02*
TAWSS Systole Plaque Segment 74.1% ± 21.5% 110.7% ± 18.4% 0.02*
TAWSS Diastole Healthy Segment 80.3% ± 20.8% 95.6% ± 24.3% 0.32
TAWSS Diastole Plaque Segment 80.0% ± 21.1% 95.0% ± 24.6% 0.33
Peak WSS Healthy Segment 75.4% ± 22.9% 111.9% ± 22.1% 0.03*
Peak WSS Plaque Segment 74.3% ± 23.1% 111.6% ± 22.9% 0.03*
Table 2. Normalized WSS Parameters.
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of the concentration or duration used, appeared to induce an increase in blood flow, but only during systole. This 
increase might be due to an Ivabradine-induced increase in stroke volume, as a prolonged diastolic phase is likely 
to result in an increase in left ventricle volume and thus a larger amount of blood leaving the left ventricle during 
systole. Due to the prolonged duration of diastole, the time-averaged blood flow during the complete cardiac cycle 
did not change in our study.
Ivabradine treatment for 6 weeks in LDLR−/− mice resulted in a reduction in endothelial inflammation21, 
suggesting that although the increase in TAWSS is of short duration, it is sufficient to affect vascular biology. 
Pre-treatment with Ivabradine has been shown to prevent plaque growth in animal models of atherosclerosis in 
some16,17 but not all20 studies. Custodis et al. and Baumhäkel et al. observed that treatment of mice with Ivabradine 
significantly reduced plaque size in the aortic root and/or the ascending aorta16,17. However, it should be noted 
that both studies examined whether Ivabradine could prevent disease (i.e. they started Ivabradine treatment with 
the onset of high fat diet) but the potential effect of Ivabradine on plaque progression was not studied. We wished 
to know whether Ivabradine can be used to treat atherosclerosis and therefore analyzed whether Ivabradine treat-
ment of an existing plaque would affect its composition. This hypothesis was supported by our previous report 
that changes in WSS over a developing plaque affects its phenotype5. However, we did not observe any changes in 
plaque composition in terms of plaque size, length, relative necrotic core area or relative macrophage accumula-
tion in our current study. Our study design with 2 weeks of Ivabradine treatment did not show an effect on plaque 
size or composition. We set out, based on our power calculation, to analyse 5 control versus 5 Ivabradine-treated 
animals. However, due to the premature death of several animals, likely due to the combination of repeated anes-
thesia and the use of imaging contrast agent, we ended up with 4 control versus 5 Ivabradine-treated animals for 
histological analysis. Considering the P values we obtained (ranging from 0.55–0.98, see Table 3) we conclude 
there is no significant effect of Ivabradine on the plaque parameters we studied in our model. If we do a power cal-
culation in hindsight, using the lowest p-value found, i.e. p = 0.55 for necrotic core 28.3 ± 10.20 versus 24.3 ± 8.4 
(Table 3), we find we would need more than a 100 animals to reach statistical significance. Therefore, our findings 
Figure 2. Ivabradine increased TAWSS during systole. (A) 3D distribution of TAWSS during systole in the 
RCCA before (t = 0) and after Ivabradine (t = 3) in a representative mouse; (B) Circumferentially-averaged 
WSS along the proximal RCCA; The proximal RCCA was divided into the healthy and the plaque segment, 
indicated by the vertical dashed line; (C) TAWSS during systole in both the healthy and the plaque segments 
were significantly increased after treatment with Ivabradine. Note: ***p < 0.001.
Plaque Composition 
Parameters
Control 
(n = 4)
Ivabradine 
(n = 5) P-value
Plaque Area (mm2) 0.32 ± 0.15 0.32 ± 0.25 0.98
Plaque Length (mm) 0.60 ± 0.28 0.72 ± 0.29 0.76
Necrotic Core (%) 28.3 ± 10.20 24.3 ± 8.4 0.55
Macrophages (%) 40.0 ± 4.5 34.6 ± 13.1 0.79
Table 3. Plaque Composition Parameters.
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point towards a lack of an effect of Ivabradine on plaque size and composition when it is administered after the 
initiation of disease. These data are in agreement with the clinical study by Fox et al. who did not observe a bene-
ficial effect of Ivabradine on clinical outcome in patients who had coronary artery disease without heart failure12.
In conclusion, Ivabradine led to a small but significant increase in flow and WSS during the systolic phase of 
the heart cycle. Due to the prolonged diastolic phase, time-averaged flow and TAWSS over the complete heart 
cycle did not change. However, increased WSS during the systolic phase only accounts for a short duration of the 
cardiac cycle. This increase did not affect plaque size or composition in our animal model. Previous clinical and 
animal studies showed inconclusive results upon treatment with Ivabradine, with no or a positive effect.
Data Availability
All data generated or analyzed during this study are included in this published article.
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